Antitumor Activity, Safety and Predictive Biomarker Results to be Presented
ROCKVILLE, Md., June 1, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces a poster presentation on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting. ENMD-2076 is currently in a Phase 2 trial for the treatment of ovarian clear cell carcinoma (OCCC) at Princess Margaret Hospital Centre in Toronto. ASCO will be held June 3 – 7, 2016 in Chicago. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website afterward.
Gynecologic Cancer:
General Poster Session
Monday, June 6, 2016, 1:00PM – 4:30PM (CDT)
Abstract No.: 5564, Poster Board No.: 387
Title: Antitumor Activity, Safety and Predictive Biomarker Results of ENMD-2076 Administered to Patients (pts) with Recurrent Ovarian Clear Cell Carcinoma (OCCC): A Trail of the Princess Margaret Phase II Consortium
Location: Hall A
About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. CASI is completing a Phase 2 trial of ENMD-2076 in ovarian cancer. In addition, CASI is conducting a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, a Phase 2 ovarian clear cell carcinomas and a Phase 2 study in fibrolamellar carcinoma (FLC). ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma and EU orphan drug designation for the use of ENMD-2076 to treat hepatocellular carcinoma (HCC) including fibrolamellar carcinomas (FLC).
About CASI Pharmaceuticals, Inc.
CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China. CASI’s product pipeline includes exclusive rights to MARQIBO® (vinCRIStine sulfate LIPOSOME injection), EVOMELA™ (CE-Melphalan HCI for injection) and ZEVALIN® (ibritumomab tiuxetan) for greater China (including Taiwan, Hong Kong and Macau). CASI’s development pipeline also includes its proprietary drug candidate ENMD-2076, a selective angiogenic kinase inhibitor currently in multiple Phase 2 oncology studies, and 2ME2 (2-methoxyestradial) an orally active compound that has antiproliferative, antiangiogenic and anti-inflammatory properties. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary with R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.
